The Parenteral Drug Association (PDA) and the U.S. Food and Drug Administration (FDA) are once again co-sponsoring the PDA/FDA Joint Regulatory Conference, which is now in its 30th year. This flagship conference consistently provides a unique opportunity to hear from and engage with numerous regulatory and industry leaders concerning the latest manufacturing, quality, supply, and related compliance issues in an ever-evolving landscape. Last year we explored the continuing evolution of innovative manufacturing capabilities and the potential effect on quality, compliance, and regulatory lifecycle paradigms. Attendees will benefit through the discussion of latest innovative technologies, case studies, regulatory expectations, and forward-looking perspectives in sessions. FDA senior officials will discuss Center-specific initiatives as well as provide compliance updates.
The conference will continue to focus on advancing quality management and the robust manufacturing of innovative drugs, biologics, and combination products. Combined efforts of industry and regulators are necessary to assure uninterrupted supplies of safe and high-quality products while advancing the use of new capabilities.